Mark Manfredi is a founding member of Ikena Oncology and has over two decades of experience in cancer drug discovery and translational research. He previously served as Chief Scientific Officer of Raze Therapeutics and as Entrepreneur-in-Residence at Atlas Venture, where he still serves as an advisor. Prior to Raze, he served as Vice President of Oncology at Takeda Pharmaceuticals where he was a member of the senior R&D management team responsible for global oncology R&D strategy. He earned his B.S. from the University of Rhode Island and his Ph.D. in Biology from Boston College.